Outcomes clinical trials at UC Health
1 research study open to new patients
The Chimerix CMX001 Registry
open to eligible people ages 6 months to 100 years
The prospective observational study is to establish a registry database to evaluate the potential impact of prior treatment with CMX001 on the long-term incidence of specific events, such as outcomes, late CMV and other Double-stranded DNA virus associated events, s well as survival rates in subjects previously enrolled in selected clinical studies of CMX001. Each Registry participant will be followed for a period of approximately 3 years from their enrollment in the Registry.
at UCSD UCLA
Last updated: